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Abstract
Background: Substantial progress has been made in the identification of sequence elements that control mRNA
splicing and the genetic variants in these elements that alter mRNA splicing (referred to as splicing quantitative trait
loci – sQTLs). Genetic variants that affect mRNA splicing in trans are harder to identify because their effects can be
more subtle and diffuse, and the variants are not co-located with their targets. We carried out a transcriptome-wide
analysis of the effects of a mutation in a ubiquitous splicing factor that causes retinitis pigmentosa (RP) on mRNA
splicing, using exon microarrays.
Results: Exon microarray data was generated from whole blood samples obtained from four individuals with a
mutation in the splicing factor PRPF8 and four sibling controls. Although the mutation has no known phenotype in
blood, there was evidence of widespread differences in splicing between cases and controls (affecting approximately
20% of exons). Most probesets with significantly different inclusion (defined as the expression intensity of the exon
divided by the expression of the corresponding transcript) between cases and controls had higher inclusion in cases
and corresponded to exons that were shorter than average, AT rich, located towards the 5’ end of the gene and
flanked by long introns. Introns flanking affected probesets were particularly depleted for the shortest category of
introns, associated with splicing via intron definition.
Conclusions: Our results show that a mutation in a splicing factor, with a phenotype that is restricted to retinal tissue,
acts as a trans-sQTL cluster in whole blood samples. Characteristics of the affected exons suggest that they are spliced
co-transcriptionally and via exon definition. However, due to the small sample size available for this study, further
studies are required to confirm the widespread impact of this PRPF8mutation on mRNA splicing outside the retina.
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Background
Splicing sits at the intersection between transcription
and translation and directly regulates both the abundance
and diversity of transcripts. It is effected by the spliceo-
some, a macromolecular complex composed of uridine-
rich snRNAs (U1, U2, U5, and U4/U6 duplex for the
U2-type spliceosome) and numerous proteins [1], which
systematically assemble at conserved sequence motifs on
newly-transcribed RNA. The spliceosome undergoes a
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series of structural rearrangements to catalyse two trans-
esterification reactions ligating adjacent exons [2]. The
PRPF8 protein mediates most spliceosomal interactions
as it interfaces with splice sites on the transcribed RNA,
snRNAs, and other proteins. Over the years, mapping of
PRPF8 protein domains has revealed numerous splicing-
related roles. For example, the 3’ fidelity region attenuates
the impact of 3’ splice site (3SS) mutations [3]. Also, the
C-terminal domain (CTD) of Prp8p (yeast homologue of
PRPF8) interacts with Snu114p and Brr2p (another pro-
tein that interacts with the CTD) to unwind and release
the U4 snRNA, which activates the spliceosome [4-8].
Recent evidence suggests a direct role in splicing through
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catalysis of the transesterification reactions [9]. It is there-
fore unsurprising that mutations in PRPF8 have been
shown to affect splicing efficiency in yeast [10], mouse
[11,12], zebrafish [13] and human [14].
Genome-wide association studies (GWAS) have
revealed a large number of genetic variants that are asso-
ciated with diseases and phenotypes but for many of
these associations the exact causal mechanism remains
unknown. A large proportion of the associations are likely
to be mediated by the effects of polymorphic variants on
gene expression. In support of this view, GWAS results
have been found to be enriched for expression quanti-
tative trait loci (eQTLs) [15]. Genetic variants may also
affect transcript processing. The contribution of variants
that affect mRNA splicing, in particular, is thought to be
substantial [16,17]. Although many studies have assessed
the impact of genetic variants acting in cis on mRNA
splicing [16,18-22] variants that act in trans have been
less extensively studied [23].
Genetic variants affecting components of the spliceo-
some can have trans-acting effects on splicing. In par-
ticular, maturation defects, structural malformations and
splicing factor mutations can lead to aberrant transcripts
due to mis-splicing, resulting in genetic diseases [24,25].
For example microencephalic osteodysplastic primordial
dwarfism type I (MOPDI), also known as Taybi-Linder
Syndrome (TALS), is caused by mutations in the minor
spliceosome resulting in incomplete splicing of a small
number of critical transcripts [26,27]. MOPDI is charac-
terised by gross developmental retardation and a lifespan
of under one year. Mutations affecting components of the
spliceosome can also have a more restricted phenotype,
such as in the case of splicing factor associated retinitis
pigmentosa (RP). RP is a broad spectrum of eye diseases
featuring gradual degeneration of rod and cone photore-
ceptors, causally associated with mutations in over 100
genes and may be autosomal dominant, autosomal reces-
sive or X-linked [28,29]. A subset of autosomal dominant
mutations are located on components of the spliceosome
PRPF3, PRPF6, PRPF8, and PRPF31 [28,30]. The progres-
sion of the disease is marked by night blindness and tunnel
vision, and in later stages, complete blindness. However,
no adverse phenotypes in non-retinal tissues are known
[23,28].
There are two hypotheses that could explain howmuta-
tions in splicing factors result in RP [14]. First, because
the pathology of the disease is restricted to the retina,
RP may be the result of aberrant splicing of a transcript
isoform that is specific to retinal tissue. Recently, tran-
scriptome analysis of retinal tissue in a mouse model of
RP revealed a large number of novel and/or aberrant tran-
scripts [12]. This hypothesis does not rule out the second
possibility: that these mutations in core components of
the spliceosome increase the transcriptome-wide rate of
splicing error and that retinal tissue is particularly sensi-
tive to this increased rate of mis-splicing. Intermediates
between these two extremes are also possible.
Here we test the hypothesis that a mutation in a splicing
factor that causes RP leads to transcriptome-wide splicing
defects in a non-retinal tissue. We used exon microar-
rays to profile transcript expression in whole blood sam-
ples obtained from RP-PRPF8 individuals bearing the
p.H2309R mutation in the splicing factor PRPF8 [29] and
paired sibling controls. For a large proportion of exons
we found evidence of differential inclusion in mature
transcripts of cases compared to controls. Differentially
spliced exons were disproportionately associated with
longer flanking introns and likely to be spliced through
exon, rather than intron definition.
Results
Transcriptome-wide perturbation of splicing
We generated exon-level microarray expression data from
four individuals with a mutation in PRPF8, a core compo-
nent of the spliceosome, and sibling controls. Preprocess-
ing and quality control steps were carried out as described
in the Methods section. Following quality control steps
and removal of probesets that were not expressed in at
least 50% of the samples, a total of 103,268 core and
149,835 full probesets remained. To test for evidence
of differential splicing we compared probeset inclusion
(defined as the log of the ratio of probeset expression
intensity to the expression intensity of the correspond-
ing metaprobeset/transcript) between cases and controls.
Comparisons were carried out separately for probesets
in four overlapping categories, defined by whether the
probeset mapped to an annotated intron or exon (referred
to as the exonic and intronic categories, respectively) and
by whether the probeset belonged to the core probesets
or to the full probesets. The latter two categories are an
aspect of the microarray design and reflect the confidence
of the exon annotations on which the probesets were
based. The core probesets correspond to high-confidence
exon annotations, while the full probesets also target
exons in computationally predicted transcripts. Intronic
probesets were further partitioned based on splice type
(major and minor).
Probeset inclusion was compared between cases and
sibling controls for each probeset that passed the detec-
tion and quality control filters described above. Instead of
using limma we used standard t-tests so that we could
estimate π0, the proportion of true null hypotheses. The
limma approach has higher statistical power to detect dif-
ferences at the individual probeset level, because it shares
information across probesets but this violates the inde-
pendence assumption when estimating π0. Consequently,
the expected distribution of p-values is no longer uniform
under the null hypothesis [31]. The histogram of p-values
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obtained from these comparisons (Figure 1) shows a large
excess of small values compared to the uniform distribu-
tion, expected under a null hypothesis of no difference in
splicing between cases and controls. Statistical methods
exist to estimate π0 from a distribution of p-values. We
used the qvalue package from BioConductor [32,33] for
this purpose. For core probesets π0 was 0.76 while full
probesets had a slightly higher value of 0.79. This sug-
gests that for approximately one fifth of the probesets
(roughly 24% for core and 21% for full probesets) the null
hypothesis of no difference in inclusion between cases and
controls does not hold. For exonic probesets π0 was 0.77
while intronic probesets had π0 = 0.81.
It is possible that this high proportion of affected probe-
sets inferred using the qvalue package could be the
result of a failure of the assumptions underlying the esti-
mation of π0 and not a consequence of differences in
splicing between the case and control groups. To inves-
tigate this possibility, we compared the estimates of π0
obtained from the true case-control groups to estimates
obtained when sample labels were permuted exhaustively
within sibling pairs (so that comparable paired t-tests
could still be carried out). The estimate of π0 for the
correctly labelled samples was lower than for any of the
eight alternative configurations that can be obtained in
this way (p = 0.125; Additional file 1: Figures S2 and S3).
In a similar way, the value of π0 was lowest for all 35
possible case-control pairings, without regard to sibling
relationships (p = 0.03). The value of π0 was strongly
anti-correlated with the number of properly paired sib-
ling pairs (Pearson r = −0.84, p = 0.008; Spearman
ρ = −0.92, p = 0.001), suggesting that the PRPF8 muta-
tion does have a transcriptome-wide effect on mRNA
splicing in whole blood samples.
Differential splicing primarily involves higher inclusion of
exons in cases
We used limma to compute p-values and t-statistics for
differential inclusion of individual probesets because this
approach has been shown to have higher statistical power
than standard t-tests for small sample sizes [34]. The
majority of probesets with significantly different inclusion
between cases and controls had higher inclusion in cases
(Figure 2; Additional file 2). Below a p-value threshold of
0.2, the enrichment for probesets with higher inclusion
in cases was highly statistically significant (core probe-
sets: p = 4.8 × 10−4, full: p = 1.3 × 10−4, exonic: 4.6 ×
10−10; Additional file 1: Table S1–S3, Additional file 1:
Figure S6). However, intronic probesets showed no sig-
nificant excess of positive t-statistics among probesets
with low p-values (p = 0.24 at p-value threshold of 0.2;
Additional file 1: Tables S4 and S5). This suggests that
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Figure 1 Empirical distribution of p-values. Each p-values was calculated using pairwise t-tests for a normalised probeset between cases and
controls.
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Figure 2 Proportion of probesets indicating higher/lower inclusion in cases for binned p-value thresholds. All bins have an equal width of
p = 0.05 for p-values in the range [ 0, 1]. Red bars symbolise the proportion of probesets indicating higher inclusion in cases; similarly, blue bars
refer to lower inclusion in cases. The absolute height of a bar of each colour represents the proportion of probesets with higher/lower inclusion in
cases. The t-statistic was used to determine relative inclusion: t > 0 - higher inclusion in cases; t < 0 - lower inclusion in cases. Plot only shows core
and exonic (full) probesets.
most of the differential splicing involves higher exon
inclusion in cases. The affected probesets tended to be
expressed at a lower level than the remainder of the probe-
sets in the meta-probeset (gene) to which they mapped.
Probesets with higher inclusion in cases had a mean
expression intensity (across cases and controls) that was,
on average, less than half the mean expression intensities
of unaffected probesets (p = 9.6×10−112). The difference
was much smaller for probesets with lower inclusion in
cases; these probesets had raw expression intensities that
were on average 14% lower than the average of the unaf-
fected probesets (p = 0.004). Thus, the affected probesets
are from low inclusion exons that are typically included
at higher levels in the mutant samples compared to
controls.
Characterisation of differentially included exons
The introns upstream of exons containing probesets with
evidence of differential inclusion between cases and con-
trols were significantly longer than average (Table 1).
Short introns (< 250 bp) are thought to be excised
primarily through intron definition, and longer introns
through exon definition [35-37]. These two classes of
introns can be seen on the density plot of intron lengths
(Figure 2). The density plot of introns bordering differ-
entially included exons had a diminished peak at short
lengths (Figure 3), suggesting that aberrant splicing in
cases does not affect splicing via intron definition. Instead,
longer introns were particularly abundant upstream of
preferentially included exons (Figure 3). Thus, differential
splicing between cases and controls appears to primarily
affect the exon definition pathway.
Exon definition occurs for short to moderate length
(< 500 bp) exons since the components of the spliceo-
some need to associate across them [38]. Long exons tend
to have additional splicing enhancer motifs, perhaps to aid
the binding of spliceosome components since they cannot
associate across the length of the exon [38].We found that
exons containing probesets with evidence of higher inclu-
sion in cases than in controls were significantly shorter
than average (Table 2). We also found that exons with
lower inclusion in cases were somewhat longer than other
exons (Table 2). Exons that showed evidence of higher
inclusion in cases relative to controls were depleted of
long exons (> 500 bp), suggesting that the majority of
these exons are spliced via exon definition [39].
We used MaxEntScan [40] to calculate splice site
scores at intron-exon junctions and compared these
between affected and unaffected exons. For exons with
higher inclusion in cases, themedian score of 5’ splice sites
(5SS) was significantly higher than background (Tables 3
and 4) but the 3’ splice sites (3SS) showed no difference in
Table 1 Length of introns flanking differentially included
exons
Upstream intron length (5’) Downstream intron length (3’)
Median p-value q-value Median p-value q-value
Up 1966 0.002 0.0064 1662 0.84 0.84
Down 2053.5 0.05 0.1 1843.5 0.14 0.18
All 1625 - - 1625 - -
Comparison of median of intron length for exons with higher (up) and lower
(down) inclusion in cases relative to controls.
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Figure 3 Distributions of intron length. Density plot of intron length (A) upstream and (B) downstream of differentially included exons in cases
relative to controls. A similar plot for background exons (core exons) is provided for reference.
score. In contrast, for exons with lower inclusion in cases,
neither the 5SS nor 3SS showed differences in scores
(Tables 3 and 4). The distributions of splice site scores are
shown in Additional file 1: Figure S4.
We found that the exons with higher inclusion in cases
had much higher proportions of A and T nucleotides than
background (core) exons and, correspondingly, lower pro-
portions of G and C nucleotides (Figure 4). Exons with
lower inclusion in cases showed no significant difference
from background. We also obtained a list of 238 candi-
date hexameric exonic splice enhancers (ESEs) [41]. For
each ESE, we counted the number of times it occurred
in each exon category and normalised this by the sum
Table 2 Length of differentially included exons
Mean Median p-value q-value
Up 368.88 127 7.52 × 10−18 1.50× 10−17
Down 562.81 166 2.44 × 10−3 2.44× 10−3
All 436.5 153 - -
Comparison of mean and median lengths for exons with higher (up) and lower
(down) inclusion in cases relative to controls.
of exon lengths in that category. Unsurprisingly, consid-
ering that ESEs are A-rich (nearly 50% of bases of the
238 ESEs were A), we found that highly included exons
did indeed show evidence of ESE-enrichment (mean ESE
prevalence of 4.14 × 10−4 against 3.70 × 10−4 for core
exons, p = 0.02). We did not observe any ESE enrich-
ment in exons with lower inclusion in cases (mean ESE
prevalence of 3.76 × 10−4, p = 0.72). The enrichment of
ESEs in the exons with increased inclusion in cases does
not explain the A+T richness because the excess of A and
T nucleotides persisted even when all instances of the 238
ESEs were removed. Indeed, the excess of ESEs may be a
consequence of the A-richness of the affected exons.
Splicing can take place co-transcriptionally (while the
polymerase is still associated with the DNA template) or
post-transcriptionally [42-48]. Exons belonging to longer
genes or located far from the 3’ ends of genes are more
likely than other exons to be spliced co-transcriptionally
[49]. To investigate whether the mutation may have a
greater impact on co- or post-transcriptional splicing we
compared gene length and distance from 3’ gene ends
between affected exons (differentially included between
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Table 3 Splice site strength of differentially included exons
Splice donors (5SS) Splice acceptors (3SS)
Mean Median p-value q-value Mean Median p-value q-value
Up 8.33 8.76 8.86× 10−3 3.54× 10−2 8.43 8.68 0.58 0.75
Down 8.12 8.68 0.75 0.75 8.19 8.40 0.10 0.19
All 8.08 8.68 - - 8.30 8.69 - -
Mean and median splice site strength computed using MaxEntScan [40].
cases and controls) and unaffected exons. We found that
the mean gene length as well as the distance from the
3’ end of the gene were both significantly greater for
affected exons (Table 5). This suggests that the muta-
tion has a larger impact on co-transcriptional splicing;
the effect may even be restricted to splicing that occurs
co-transcriptionally.
Discussion
Cis-acting factors have been shown to be important reg-
ulators of alternative splicing and several previous stud-
ies have reported cis-acting genetic variants that affect
mRNA splicing [16,18-21,50-52]. Such cis-acting splicing
quantitative trait loci (sQTLs) typically affect the splic-
ing of a single gene. Trans-acting variants, however, can
have widespread impact and when they affect ubiquitous
components of the transcript processing machinery the
effects may be transcriptome-wide. To date, there have
been fewer studies on trans-sQTLs than on cis-acting
variants. Given that almost all human genes are spliced
and a large majority of multi-exon genes are alternatively
spliced, often in a tissue-specific manner [53], cis- and
trans-acting factors that cause splicing errors or affect the
regulation of alternative splicing have the potential to have
a substantial impact on the transcriptome. Indeed, a large
proportion of human genetic diseases are likely to result
from mutations that affect splicing [25,53-55].
In this study, we applied statistical analyses that inter-
rogated exon inclusion events across the human tran-
scriptome. We estimated the transcriptome-wide effect
of the PRPF8 mutation by using the π0 statistic, which
in the context of multiple hypothesis testing, is an esti-
mate of the proportion of tests that conform to the null
Table 4 Combined splice site strength (5SS and 3SS) of
differentially included exons
Sum of 5SS and 3SS scores
Mean Median p-value q-value
Up 16.76 17.12 0.04 0.08
Down 16.31 16.77 0.11 0.11
All 16.38 16.99 - -
Similar to Table 3 but using combined splice site strength.
hypothesis. This approach has previously been applied
in transcriptome-wide studies of population differential
gene expression between human populations [56] and,
more recently, in the study of cis- and trans-expression
quantitative loci [22]. The observed value of π0 was
the lowest among all permutations of the case-control
labels. Nevertheless, we acknowledge that, given the rela-
tively small sample size in this study, this finding requires
independent validation particularly given the often noisy
nature of microarray data.
Our results provide evidence that a non-synonymous
mutation in the splicing factor PRPF8 that leads to retini-
tis pigmentosa affects the inclusion of approximately 20%
of the exons in genes expressed in whole blood samples.
Affected exons were most often included at a higher level
in the transcripts of cases than of controls. Averaging
across all samples (cases and controls), these exons had
lower inclusion levels than unaffected exons, suggesting
that they are absent from some of the transcripts of the
corresponding gene. The fact that the mutated form of
PRPF8 was associated with higher inclusion of exons that
appear to be skipped in some transcripts was an unex-
pected result. It suggests that the mutation may affect
alternative splicing (e.g. tissue-specific regulation of alter-
native splice isoforms) rather than giving rise to a high rate
of splicing errors involving skipping of constitutive exons
or intron retention. Exon skipping is the most common
type of alternative splicing event [57]. Because the muta-
tion is associated with higher inclusion levels of exons that
are expressed at relatively low levels, we propose that the
PRPF8 mutation may reduce the likelihood of exon skip-
ping. Under thismodel the adverse phenotype could result
from failure of a regulated exon skipping event which is
required in retina. The exon microarray platform we used
also includes some probesets that map to intronic regions.
Although the number of expressed probesets mapping
to introns was far lower than for exons, we found some
evidence of differential intron retention between cases
and controls. However, the proportion of affected probe-
sets was lower for intronic compared to exonic probesets
and the overall effect was approximately equally divided
between increased and decreased intron inclusion.
The introns upstream of exons with higher inclusion in
cases were significantly longer than average. In fact, short
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Figure 4 Nucleotide content of differentially included exons. The proportion of each nucleotide in differentially included exons.
introns were almost entirely absent upstream of affected
exons (Figure 3). Short introns (< 250 bp) are more
efficiently excised through the assembly of spliceosomal
components across the intron before pairing up (intron
definition) and they generally have weaker splice sites [58].
Long introns rely on spliceosome components first assem-
bling across exons before juxtaposing across the target
introns.
One of the most striking features of probesets with
significantly different inclusion in cases compared to con-
trols was that they were found predominantly on shorter
exons. Themajority of affected exons had increased inclu-
sion in cases and we found that shorter exon length
applied only to these exons. In fact, probesets with lower
inclusion in cases compared to controls mapped to exons
that were slightly longer than the background unaffected
exons. Exon defined splicing is most efficient when exon
length is between 50 and 500 bp [35,39,59]. Splicing via
intron definition requires short introns (< 250 bp) and,
as discussed above, these were depleted among introns
flanking affected exons, particularly for the exons with
higher inclusion in cases. Consequently, we propose that
the PRPF8 mutation affects splicing via exon definition,
but may have no effect on splicing via intron definition.
We also observed that exons with higher inclusion in cases
tended to have stronger 5’ splice site (5SS). Interestingly,
PRPF8 is known to interact directly with the 5SS [2] (and
references therein). It contacts the 5SS dinucleotide at
residues QACLK (positions 1894–1898) as part of the U5
snRNP (a constituent of theU5·U4/U6 tri-snRNP) [60-63].
However, the RPmutation is a histidine to arginine change
at residue 2309 [29] suggesting that the mutation does not
directly affect contact with the 5SS andmay, instead, affect
interaction with another protein or snRNA.
On average, exons that were differentially included
between cases and controls were much further from 3’
gene ends and belonged to significantly longer genes
than unaffected exons. Both distance from the 3’ end
and gene length are associated with the efficiency of
co-transcriptional splicing [49]. The majority of affected
Table 5 Indicators of co-transcriptional splicing
Gene length Distance from 3’ end
Mean Median p-value q-value Mean Median p-value q-value
Up 100,954 53,464 2.6 × 10−7 5.2 × 10−7 51,939 23,542 7.3 × 10−10 1.4 × 10−9
Down 103,781 53,741 3.9 × 10−5 3.9 × 10−5 58,279 21,426 5.1 × 10−5 5.1 × 10−5
All 91,811 42,729 - - 46,338 14,514 - -
Gene length and distance from the 3’ end of genes for exons differentially included.
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exons had higher inclusion in cases and exons with higher
inclusion in cases (but not exons with lower inclusion) had
significantly greater proportions of A and T nucleotides
than unaffected exons. A-rich tracts have been observed
to lead to pol II pausing [64,65], potentially increasing the
time available for mRNA splicing to occur prior to the
completion of transcription. Taking these observations
together we propose that the PRPF8 mutation may pri-
marily or, at least, disproportionately affect splicing that
takes place co-transcriptionally.
Two previous studies of the effects of mutations in three
splicing factors (PRPF3, PRPF8 and PRPF31) linked to
retinitis pigmentosa on mRNA splicing in lymphoblast
cells reported evidence of retained introns [11,14]. Both
of these studies investigated splicing for a small number
of introns. Only one intron showed evidence of retention
associated with the mutation in PRPF8 [14]. This was a
U12-type intron (the third intron of STK11). However, the
corresponding probesets did not show evidence of expres-
sion above background, thus we did not find evidence
to support retention of this intron in our dataset. Fur-
thermore, we did not find any evidence of retention of
U12-type introns in cases (Additional file 1: Figure S5).
We observed that exons with specific structural char-
acteristics were more likely to be differentially-included:
short exons flanked by long introns, high A+T-content,
located towards the 5’ end of the gene. It is possible
that these exons are more prone to microarray hybridi-
sation noise. For example, it can be more difficult to
design microarray probesets targeting short exons (short
sequences limit the choices of array probes), resulting in
lower hybridisation affinity. Indeed, we observed higher
variability of expression signals in affected exons com-
pared to unaffected exons even when restricting to con-
trols alone (data not shown). Nevertheless, given that
sample preparation and processing was carried out inde-
pendent of treatment labels, technical noise should not
be biased towards increased exon inclusion in cases. Our
results suggest that a mutation in PRPF8, implicated in
RP, has a subtle effect on the inclusion of a large num-
ber of human exons. However, further investigation using
newer sequencing based technologies (RNA-Seq) and an
independent set of samples will enable the impact of the
mutation on splicing error to be confirmed and dissected
in greater detail.
Conclusion
Overall, our results support the hypothesis that a muta-
tion in the splicing factor PRPF8 that leads to retinitis
pigmentosa, has a widespread impact on mRNA splic-
ing across the transcriptome. Given that splicing of such
a large proportion of exons is effected by the mutation
in blood, it is surprising that the phenotype associated
with this mutation is restricted to the retina. However,
because the differentially included probesets were from
exons with low inclusion overall and had higher inclu-
sion in cases compared to controls, we propose that
the mutation does not lead to an increase in the rate
of mis-splicing of constitutive exons. Instead, the muta-
tion may influence the inclusion of alternatively spliced
exons. Consequently, we suggest that the disease pheno-
type in retinal tissue could result from failure to produce
one or several retina-specific isoforms that require exon
skipping.
Methods
Exon array sample preparation and data generation
This project was approved by theUniversity of Cape Town
Research Ethics Committee (REC REF: 180/2009), which
is in compliance with the guidelines of the declaration of
Helsinki. Written informed consent for participation in
the study was obtained from participants.
Blood from five individuals carrying the autosomal
dominant RP mutation p.H2309R (referred to as cases)
together with that from unaffected sibling controls was
collected and preparation coordinated to ensure equal
sample incubation times. Three blood samples per sub-
ject were collected into PAXgene™ tubes (PreAnalytiX),
according to the manufacturer’s instructions, and incu-
bated at room temperature. RNA extractions were per-
formed 16 hours (A sample), 20 hours (B sample) and
39 hours (C sample) after collection. Total RNA was
extracted using the PAXgene™ Blood RNA kit, follow-
ing the manufacturer’s recommended protocol. The RNA
samples were not heat denatured following elution, but
immediately stored at -80°C.
The A and B RNA isolations of each sample were
pooled, and the Affymetrix GeneChip® Blood RNA Con-
centration Kit used to concentrate the RNA. Quality con-
trol checks to determine RNA concentration and integrity
were performed for each sample, using the Nanodrop
(Thermo Scientific) and Agilent 2100 Bioanalyser (Agilent
Technologies), respectively. The RNA integrity number
(RIN) quality threshold used was 7. It was determined
that one of the cases showed poor integrity of A/B and
C RNA samples leading to its exclusion together with
its sibling-pair. RNA yields of between 2.22 and 5.16 μg
were obtained for the remaining samples, which were of
satisfactory integrity to proceed with microarray analy-
sis. The 260/280 ratios for the samples ranged from 1.97
to 2.06. All samples exceeded the RNA integrity number
(RIN) quality threshold ≥ 7, as samples ranged from RIN
8.3–9.10.
Ribosomal RNA reduction was performed on the eight
remaining samples using the RiboMinus™ Transcriptome
Isolation Kit (Human/Mouse) (Invitrogen), in accordance
with a modified Affymetrix protocol. The RNA was then
processed with the Whole Transcript (WT) Sense Target
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Labelling assay. The labelled samples were hybridised to
Affymetrix GeneChip® Human Exon Array 1.0 ST chips
according to the prescribed protocol. A total of 5.5 μg
of single stranded cDNA (generated from cRNA) was
hybridised to the arrays. Following hybridization, the
arrays were scanned in theAffymetrix GeneChip® Scanner
3000 7G.
Cases were labelled T1, T2, T3, and T4 and correspond-
ing sibling controls C1, C2, C3, and C4.
Array quantification and intensity normalisation
Raw exon array intensities were summarised into probe-
sets and metaprobesets at the core and full probe-
set/metaprobeset level using Affymetrix Power Tools
(APT) by the robust multi-chip averaging (RMA) algo-
rithm [66]. Quality control of array data was carried out
according to a previously described procedure [67]. We
applied hierarchical clustering and principal components
analysis to the raw intensities to identify possible outliers
(Additional file 1: Figure S1). APT was also used to deter-
mine probesets and metaprobesets that were detectable
above the background (DABG) [68]. We excluded from
further analysis all probesets that were detectable above
background in fewer than half of the samples. We also
used the annotation files provided by Affymetrix to
exclude all probesets with probes likely to cross-hybridise.
A similar procedure was applied to metaprobesets: only
those having at least half of the associated probesets
expressed above background in all samples were retained
[67]. Finally, we normalised each probeset intensity by
subtracting its value from its parent metaprobeset inten-
sity since these values lie on a logarithmic scale [69].
The number of probesets remaining after these filtering
steps were 103,268 and 149,835 for the core and full sets,
respectively.
All analyses were performed on the hg19 build of the
human genome. Exon boundaries and splice sites were
defined based on build 66 of the Ensembl database of gene
models [70]. Exonic and intronic probesets were isolated
using the R tool xmapcore, using the database based on
build 66 of the Ensembl genemodel [71].U12-type introns
were obtained from the U12DB [72] with coordinates
modified to hg19 using liftOver [73].
Testing for differential splicing
For each probeset, log-transformed expression intensities
of probesets were compared between cases and controls.
The log-transformed expression intensities were normal-
ized by subtracting the log expression intensities of cor-
responding metaprobesets from that of probesets. We
compared the expression intensity for each probeset using
paired tests first using Welch t-tests from the standard R
library then using moderated paired t-tests implemented
in the limma [34] package. Correction formultiple testing
was based on the q-value method as implemented in the
R package qvalue [32]. The qvalue package was also
used to estimate π0, the expected proportion of tests
consistent with the null hypothesis.
Characterisation of differentially spliced exons
To avoid the potential for bias resulting from exons to
which multiple probesets mapped or individual probe-
sets that mapped to multiple overlapping exons, we con-
structed a one-to-one mapping of probesets to exons by
randomly sampling at most one exon for each probeset
and one probeset for each exon. We compared the char-
acteristics of exons for which the corresponding probeset
was differentially included between cases and controls
using a significance threshold of 0.01. Exons with signif-
icantly higher and lower inclusion levels in cases relative
to controls were considered separately and, in each cat-
egory, eight features of the exon (5’ and 3’ splice site
scores, length of up and downstream introns, exon length,
nucleotide content, distance from the 3’ end and asso-
ciated gene length) were compared between the signif-
icantly included/excluded exons and the remainder of
the exons tested. For each feature, we compared groups
using a non-parametric test (Wilcoxon rank-sum test), fol-
lowed by correction for multiple testing either using the
Benjamini-Hochberg method [74] or the q-value method
[32].
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